VAERS data released today showed 192,954 reports of adverse events following COVID vaccines, including 4,057 deaths and 17,190 serious injuries between Dec. 14, 2020 and May 7, 2021.
Source: Children’s Health Defense
The number of reported deaths following COVID vaccines topped 4,000 according to data released today by the Centers for Disease Control and Prevention (CDC). The data comes directly from reports submitted to the Vaccine Adverse Event Reporting System (VAERS).
Article by Megan Redshaw from Children’s Health Defense.
VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed.
Every Friday, VAERS makes public all vaccine injury reports received as of a specified date, usually about a week prior to the release date. Today’s data show that between Dec. 14, 2020 and May 7, a total of 192,954 total adverse events were reported to VAERS, including 4,057 deaths — an increase of 220 over the previous week — and 17,190 serious injuries, up 1,176 since last week.
In the U.S., 254.8 million COVID vaccine doses had been administered as of May 7. This includes 110 million doses of Moderna’s vaccine, 136 million doses of Pfizer and 9 million doses of the Johnson & Johnson (J&J) COVID vaccine.
This week’s VAERS data show:
- 21% of deaths were related to cardiac disorders.
- 54% of those who died were male, 44% were female and the remaining death reports did not include gender of the deceased.
- The average age of death was 74.8 and the youngest deaths reported include two 15-year-olds (VAERS I.D. 1187918 and 1242573 ) and a 16-year-old (VAERS I.D. 1225942). There were other reported deaths in children under 16 that could not be confirmed or contained obvious errors.
- As of May 7, 987 pregnant women reported adverse events related to COVID vaccines, including 297 reports of miscarriage or premature birth.
- Of the 1,950 cases of Bell’s Palsy reported, 50% were reported after Pfizer-BioNTech vaccinations, 42% following vaccination with the Moderna vaccine and 192 cases, or 10%, of Bell’s Palsy cases were reported in conjunction with J&J.
- There were 181 reports of Guillain-Barré Syndrome with 40% of cases attributed to Pfizer, 41% to Moderna and 23% to J&J.
- There were 55,220 reports of anaphylaxis with 38% of cases attributed to Pfizer’s vaccine, 49% to Moderna and 12% to J&J.
CDC find’s ‘plausible’ link between J&J vaccine and blood clotsOn May 13, The Defender reported officials with the CDC acknowledged a “plausible causal association” between J&J’s COVID vaccine and potentially life-threatening blood clot disorders after identifying 28 cases — including three deaths — among people who received the vaccine.
Dr. Tom Shimabukuro, deputy director of the CDC’s immunization safety office, identified 28 cases of rare blood clots in VAERS among people vaccinated with the J&J shot.
Shimabukuro said four of the 28 people remained in the hospital as of May 7, one of whom was in the ICU. Two were discharged to a post-acute care facility, 19 patients were discharged and three resulted in deaths.
Current evidence “suggests a plausible causal association” with the J&J vaccine and cases of thrombosis with thrombocytopenia syndrome, Shimabukuro said. The CDC’s Dr. Sara Oliver said the benefits of the vaccine still outweigh the risk and no updates to vaccine policy are needed at this time.
Children’s Health Defense queried the VAERS data for adverse events associated with the formation of clotting disorders and other related conditions and found 3,272 reports for all three vaccines from Dec. 14, 2020, through May 7.
FDA approves Pfizer vaccine for adolescents ages 12 to 15
NPR reported May 10 the U.S. Food and Drug Administration (FDA) said children 12 to 15 years old are now eligible to be vaccinated for COVID as the agency expanded its Emergency Use Authorization (EUA) for the Pfizer-BioNTech vaccine.
Pfizer submitted an amendment to their current EUA for an unapproved product on April 9 to expand use of its vaccine for adolescents ages 12 to 15 — with only six months of clinical data.
“Parents and guardians can rest assured that the agency undertook a rigorous and thorough review of all available data, as we have with all of our COVID-19 vaccine emergency use authorizations,” Dr. Janet Woodcock, the acting FDA commissioner, said.